Journal
STEM CELL RESEARCH & THERAPY
Volume 11, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13287-020-01699-3
Keywords
Stem cell therapy; Acute lung injury; Influenza virus; Coronaviruses; Mesenchymal stem cells; Lung stem; progenitor cells
Funding
- National Science Foundation of China [81771226, U1804186]
- Department of Science and Technology of Henan Province [201100311200, 19IRTSTHN003]
- Special Projects of Xinxiang City [20GG001, 20172DCG-03]
- Xinxiang Medical University [20GG001, 20172DCG-03]
Ask authors/readers for more resources
Acute lung injury (ALI), an increasingly devastating human disorder, is characterized by a multitude of lung changes arising from a wide variety of lung injuries. Viral infection is the main cause of morbidity and mortality in ALI and acute respiratory distress syndrome (ARDS) patients. In particular, influenza virus, coronavirus, and other respiratory viruses circulate in nature in various animal species and can cause severe and rapidly spread human infections. Although scientific advancements have allowed for rapid progress to be made to understand the pathogenesis and develop therapeutics after each viral pandemic, few effective methods to treat virus-induced ALI have been described. Recently, stem cell therapy has been widely used in the treatment of various diseases, including ALI. In this review, we detail the present stem cell-based therapeutics for lung injury caused by influenza virus and the outlook for the future state of stem cell therapy to deal with emerging influenza and coronaviruses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available